11 feb 2019 "With the first patient starting treatment, we have achieved another key milestone for Immunicum," added Carlos de Sousa, CEO of Immunicum.

Jan 15, 2018 Immunicum was previously listed on Nasdaq First North Premier and is the first Nasdaq (Nasdaq: NDAQ) announces that Immunicum AB (short name: IMMU), for the company,” said Carlos de Sousa, CEO of Immunicum.

Gretchen Schweitzer and Joanne Tudorica Trophic Communications Telephone: +49 172 861 8540 E-mail: ir@immunicum.com About Immunicum AB (publ) Publiceringsdatum Utgivare Person i ledande ställning Befattning Närstående Karaktär Instrumentnamn ISIN Transaktionsdatum Volym Volymsenhet Pris Valuta Immunicum AB (publ; First North Premier: IMMU.ST) a biopharmaceutical company advancing a novel immune-priming cancer treatment against a variety of solid tumors, today announced that CEO Carlos de Sousa will present the Company as well as provide background on the previously announced proposed Rights Issue at two upcoming investor events. Pressmeddelande 22 mars 2019 Immunicum AB (publ) meddelar kommande konferenser i mars och april Immunicum AB (publ; IMMU.ST) meddelar idag att medlemmar av ledn Carlos de Sousa avgår som vd för Immunicum AB (publ) Pressmeddelande. 13 december 2019. Carlos de Sousa avgår som vd för Immunicum AB (publ) Styrelsen i Immunicum har kommit överens med Carlos de Sousa om att han lämnar rollen som verkställande direktör för Immunicum med omedelbar verkan. New CEO – Carlos de Sousa. 08:37; Immunicum today announced the appointment of Carlos de Sousa as Immunicum’s Chief Executive Officer effective on October 1, 2016.Mr. de Sousa brings more than 25 years of relevant experience in the international pharmaceutical and biotech industries, including senior positions at Nycomed/Takeda, Pfizer, Novartis, BBB Therapeutics, Newron Pharmaceuticals The Board of Directors of Immunicum announced today that, by mutual agreement, Carlos de Sousa has resigned as CEO of Immunicum effective immediately.

Immunicum ab carlos de sousa

Linkedin; NASDAQ Market News. Click here to email author. NEXT STORY Bavarian Nordic Receives Antitrust Clearance for Acquisition of Rabipur/RabAvert and Encepur from GlaxoSmithKline. Publication date Issuer Person discharging managerial responsibilities Position Closely associated Nature of transaction Instrument name ISIN Transaction date IMMUNICUM AB | 7 followers on LinkedIn | Annan naturvetenskaplig och teknisk forskning och utveckling Publiceringsdatum Utgivare Person i ledande ställning Befattning Närstående Karaktär Instrumentnamn ISIN Transaktionsdatum Volym Volymsenhet Pris Valuta Carlos de Sousa, CEO, Immunicum Telephone: +46 (0) 31 41 50 52 E-mail: info@immunicum.com. Michaela Gertz, CFO, Immunicum Telephone: +46 70 926 17 75 E-mail: ir@immunicum.com Media Relations . Gretchen Schweitzer and Joanne Tudorica Trophic Communications Telephone: +49 172 861 8540 E-mail: ir@immunicum.com About Immunicum AB (publ) Publiceringsdatum Utgivare Person i ledande ställning Befattning Närstående Karaktär Instrumentnamn ISIN Transaktionsdatum Volym Volymsenhet Pris Valuta Immunicum AB (publ; First North Premier: IMMU.ST) a biopharmaceutical company advancing a novel immune-priming cancer treatment against a variety of solid tumors, today announced that CEO Carlos de Sousa will present the Company as well as provide background on the previously announced proposed Rights Issue at two upcoming investor events. Pressmeddelande 22 mars 2019 Immunicum AB (publ) meddelar kommande konferenser i mars och april Immunicum AB (publ; IMMU.ST) meddelar idag att medlemmar av ledn Carlos de Sousa avgår som vd för Immunicum AB (publ) Pressmeddelande.

Gretchen Schweitzer and Joanne Tudorica Trophic Communications Telephone: +49 172 861 8540 E-mail: ir@immunicum.com About Immunicum AB (publ) Publiceringsdatum Utgivare Person i ledande ställning Befattning Närstående Karaktär Instrumentnamn ISIN Transaktionsdatum Volym Volymsenhet Pris Valuta Immunicum AB (publ; First North Premier: IMMU.ST) a biopharmaceutical company advancing a novel immune-priming cancer treatment against a variety of solid tumors, today announced that CEO Carlos de Sousa will present the Company as well as provide background on the previously announced proposed Rights Issue at two upcoming investor events. Pressmeddelande 22 mars 2019 Immunicum AB (publ) meddelar kommande konferenser i mars och april Immunicum AB (publ; IMMU.ST) meddelar idag att medlemmar av ledn Carlos de Sousa avgår som vd för Immunicum AB (publ) Pressmeddelande.

The Board of Directors of Immunicum announced today that, by mutual agreement, Carlos de Sousa has resigned as CEO of Immunicum effective immediately. The Board has appointed Alex Karlsson-Parra

Click here to watch the full video interview: https://lnkd.in/eAFGt5r. Deprecated: Theme without comments.php is deprecated since version 3.0.0 with no alternative available.

2019-12-13

13 december 2019.

The Board has appointed Alex Karlsson-Parra Press Release 13 December 2019 Immunicum AB (publ) Announces Resignation of Carlos de Sousa as CEO The Board of Directors of Immunicum announced today that, by Carlos de Sousa avgår som vd för Immunicum AB (publ) Styrelsen i Immunicum har kommit överens med Carlos de Sousa om att han lämnar rollen som verkställande direktör för Immunicum med omedelbar verkan. Styrelsen har utsett Alex Karlsson-Parra, idag forskningschef, till tillförordnad vd. Styrelsen kommer att inleda rekrytering av en ny Immunicum AB (publ)| Östermalmstorg 5, 114 42 Stockholm| Tel +4687328 400| Orgnr. 556629-1786|immunicum.se . Pressmeddelande . 13 december 2019 .
Mosjö skola

VD, Carlos Freitas de Sousa. Styrelseordf. Michael Carlos de Sousa, VD, Immunicum Telefon: +46 (0) 31 41 50 52. E-post: info@immunicum.com.

Styrelsen har utsett Alex Karlsson-Parra, idag forskningschef, till tillförordnad vd. Styrelsen kommer att inleda rekrytering av en ny Immunicum AB (publ)| Östermalmstorg 5, 114 42 Stockholm| Tel +4687328 400| Orgnr. 556629-1786|immunicum.se .
Ola palmqvist

us gdp growth graph
frisyrer på 60 talet
ostgota biblioteket linköping
mooc based bachelors degree
transdisciplinary learning

The Secured Rights Issue. Immunicums Chairman of the Board, Agneta Edberg and CEO Carlos de Sousa discuss the Rights Issue. Listen to the live Q&A session that followed the presentation:

Stockholm, Sweden Chief Business Officer Zealand 1553 andre med navnet Carlos de Sousa er på LinkedIn Se andre med navnet Carlos de Sousa Carlos’ merke på offentlig profil 2020-02-13 2019-12-13 Carlos De Sousa is Chief Executive Officer at Ultimovacs AS. See Carlos De Sousa's compensation, career history, education, & memberships. Immunicum AB Presents Updated Data from Phase II MERECA Trial of Ilixadencel in Kidney Cancer at ASCO-SITC Clinical Immuno-Oncology Symposium Immunicum AB (publ) Announces Resignation of Carlos de Sousa as CEO . Download File.